- Home
- HOND vs ACRV Comparison
HOND vs ACRV Comparison
Compare HOND & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOND
- ACRV
- Stock Information
- Founded
- HOND 2024
- ACRV 2018
- Country
- HOND United States
- ACRV United States
- Employees
- HOND N/A
- ACRV N/A
- Industry
- HOND
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- HOND
- ACRV Health Care
- Exchange
- HOND NYSE
- ACRV Nasdaq
- Market Cap
- HOND 287.5M
- ACRV 247.8M
- IPO Year
- HOND 2024
- ACRV 2022
- Fundamental
- Price
- HOND $10.00
- ACRV $7.88
- Analyst Decision
- HOND
- ACRV Strong Buy
- Analyst Count
- HOND 0
- ACRV 5
- Target Price
- HOND N/A
- ACRV $22.60
- AVG Volume (30 Days)
- HOND 1.0K
- ACRV 44.0K
- Earning Date
- HOND 01-01-0001
- ACRV 11-13-2024
- Dividend Yield
- HOND N/A
- ACRV N/A
- EPS Growth
- HOND N/A
- ACRV N/A
- EPS
- HOND N/A
- ACRV N/A
- Revenue
- HOND N/A
- ACRV N/A
- Revenue This Year
- HOND N/A
- ACRV N/A
- Revenue Next Year
- HOND N/A
- ACRV N/A
- P/E Ratio
- HOND N/A
- ACRV N/A
- Revenue Growth
- HOND N/A
- ACRV N/A
- 52 Week Low
- HOND $9.97
- ACRV $3.19
- 52 Week High
- HOND $11.01
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- HOND N/A
- ACRV 48.60
- Support Level
- HOND N/A
- ACRV $7.69
- Resistance Level
- HOND N/A
- ACRV $8.54
- Average True Range (ATR)
- HOND 0.00
- ACRV 0.34
- MACD
- HOND 0.00
- ACRV -0.03
- Stochastic Oscillator
- HOND 0.00
- ACRV 23.59
About HOND HCM II ACQUISITION CORP
HCM II Acquisition Corp is a blank check company.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.